Myovant Sciences Announces Recipients of “Forward for Health Equity” Grants to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

On March 23, 2021 Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, reported the four recipients of its Forward for Health Equity grants (Press release, Myovant Sciences, MAR 23, 2021, https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-recipients-forward-health-equity [SID1234577044]). The grant program provides funding to nonprofit healthcare organizations with innovative projects focused on improving healthcare access, with an initial focus on reducing racial disparities in prostate cancer and uterine fibroids in the U.S. The recipients will receive up to $50,000 each.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Now more than ever, it is critical to address inequities in healthcare – so we are incredibly excited to announce the inaugural recipients of our Forward for Health Equity grants," said Jarrad Aguirre, M.D., Head of Corporate Strategy and Advocacy at Myovant Sciences, Inc. "The recipients have all proposed innovative initiatives that have great potential to address the unacceptable inequities that too many patients with prostate cancer and uterine fibroids face. We are proud to support these important organizations and build on our commitment to improving healthcare access and redefining care."

The 2021 Forward for Health Equity grant recipients are:

Prostate Cancer:

Emmanual Health Education, Inc. for "The Black Walnut: Sowing Roots for Health Equity and Health Access," to promote prostate cancer screening and health education around The Black Walnut, a documentary film that examines barriers to care for Black men.
University of California, San Francisco for "Leveraging Technology to Achieve Equity for Men with Prostate Cancer on Androgen Deprivation Therapy," to develop and test a multilingual, digital personalized lifestyle program to improve care for men with advanced prostate cancer receiving androgen deprivation therapy.
Uterine Fibroids:

The Center for Black Health & Equity for "S.I.P. and Share: Women Supporting Women," to establish a culturally appropriate outreach initiative that addresses knowledge gaps around uterine fibroids, medical mistrust and bias, and access to healthcare.
Boston Medical Center for "Center of Excellence for Patients with Uterine Fibroids in a Safety-Net Setting," to create a Fibroid Center to provide multidisciplinary care and implement an innovative, community-partnered patient engagement model at Boston Medical Center.
"Prostate cancer and uterine fibroids disproportionately impact Black Americans, and inequities in healthcare access exacerbate these disparities," said Reggie Ware, Chief Executive Officer of BlackDoctor.org and member of the grant review committee. "The recipients of the Forward for Health Equity grants have a demonstrated commitment to reducing racial disparities, and I look forward to seeing the impact they achieve in their communities through these innovative initiatives."

Myovant Sciences launched the Forward for Health Equity grant program in September 2020 to reduce disparities in healthcare and support innovative projects focused on improving access to care. Applications were reviewed by a grant review committee of Myovant employees and external leaders, including Reggie Ware (BlackDoctor.org), Jessica Shepherd, M.D. (Baylor University Medical Center), and Kelvin Moses, M.D., Ph.D. (Vanderbilt University Medical Center). The committee chose grant recipients based on their potential to improve health equity, degree of innovation, and focus on healthcare access.

Viracta and XOMA Announce Multi-License Milestone and Royalty Monetization Transaction

On March 23, 2021 Viracta Therapeutics, Inc. (Nasdaq: VIRX), and XOMA Corporation (NASDAQ: XOMA) reported XOMA has purchased the potential future milestones and royalties associated with existing licenses relating to two clinical-stage drug candidates that were obtained in Viracta’s merger with Sunesis Pharmaceuticals in exchange for an upfront payment of $13.5 million and up to $20 million in a pre-commercialization, event-based milestone (Press release, Viracta Therapeutics, MAR 23, 2021, View Source [SID1234577043]). The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, which recently initiated a pivotal Phase 2 with DAY101 in pediatric low-grade glioma. The second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma as a potential treatment for acute myeloid leukemia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This transaction with XOMA offered a unique opportunity for Viracta to secure meaningful non-dilutive capital and further strengthen our balance sheet prior to the initiation of our registration trial for the treatment of relapsed/refractory Epstein-Barr virus (EBV)-positive lymphoma and our Phase 1b/2 trial in EBV-positive solid tumors," said Dan Chevallard, Chief Operating Officer and Chief Financial Officer of Viracta. "We look forward to evaluating opportunities to strategically deploy this capital to further develop, expand and diversify our portfolio and pipeline."

"We congratulate Viracta for their recent successful merger. XOMA’s purpose-built milestone and royalty acquisition-focused business provides an alternative source of capital and offers an ideal solution for companies like Viracta to capitalize on the opportunity to divest non-strategic assets," commented Jim Neal, Chief Executive Officer of XOMA. "We like both Day One and Denovo’s thoughtful clinical development approaches, and we look forward to seeing them progress."

Under the terms of the agreement, XOMA has acquired potential royalty economics related to DAY101 and up to $54 million in pre-commercialization, event-based milestones and high single-digit net royalties on sales related to vosaroxin and up to $57 million in regulatory and commercial milestones.

EDAP TMS SA to Announce Fourth Quarter and Full Year 2020 Financial Results on March 30, 2021

On March 23, 2021 EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported that it will release its financial results for the fourth quarter and year ended December 31, 2020 after the markets close on Tuesday, March 30, 2021 (Press release, EDAP TMS, MAR 23, 2021, View Source [SID1234577042]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An accompanying conference call and webcast will be conducted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Wednesday, March 31, 2021. Please refer to the information below for conference call dial-in information and webcast registration.

Resolution at the Extraordinary General Meeting in BioInvent on March 23, 2021

On March 23, 2021 BioInvent International AB’s (publ) ("BioInvent") (Nasdaq Stockholm: BINV) Extraordinary General Meeting (the "EGM") reported to approve the Board of Directors’ resolution on a directed share issue of 16,260,601 new shares (Press release, BioInvent, MAR 23, 2021, View Source,be%20completed%20according%20to%20plan. [SID1234577041]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The EGM resolved to approve the Board of Directors’ previous resolution on February 23, 2021 on a directed share issue of 16,260,601 shares, whereby the share capital increases by SEK 3,252,120.20. For delivery technical reasons, Pareto Securities AB subscribes for all the new shares at a subscription price corresponding to shares’ quota value, for immediate further transfer on behalf of the Company to the investors participated in the directed issue at a price of SEK 50.36 per share. The new shares are expected to be admitted to trading on March 29, 2021 and the prospectus for admission to trading is expected to be published on March 26, 2021.

The minutes from the extraordinary general meeting will be available on the Company’s website, www.bioinvent.com.

About the directed share issue
Through the directed share issue published in February 2021, BioInvent receives proceeds amounting to approximately SEK 962 million (approximately USD 116 million) before transaction costs. The directed share issue consists of two separate tranches: the already performed first tranche amounting to 2,834,399 new shares, based on the authorization granted by the Extraordinary General Meeting held on 27 November 2020 and the second tranche of 16,260,601 new shares which were approved at today’s Extraordinary General Meeting.

Investors in the directed share issue are a range of international and Swedish institutional investors.

The proceeds from the share issue are intended to fund the continued transformation of BioInvent and expansion of the Company’s clinical programs.

BIOGEN TO PARTICIPATE IN THE STIFEL 3RD ANNUAL CNS DAY

On March 22, 2021 Biogen Inc. (Nasdaq: BIIB) reported that it will participate in the Stifel 3rd Annual CNS Day. The webcast will be live on Wednesday, March 31, at 12:00 p.m. ET (Press release, Biogen, MAR 22, 2021, View Source [SID1234577040]). To access the live webcast, please visit Biogen’s Investors section at www.investors.biogen.com. An archived version of the webcast will be available following the presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!